Peloton’s PT2977 leads to partial response rate of 22% in RCC patients

Peloton said once-daily 120 mg PT2977 led to a confirmed partial response rate of 22% among 55 evaluable previously treated patients with advanced renal cell carcinoma in the Phase II portion of a Phase I/II trial. Median progression-free survival (PFS) has not yet been reached at a median follow-up of 9 months.

Data were presented at the European International Kidney Cancer Symposium in Dubrovnik...